论文部分内容阅读
目的探讨XPD751基因多态性与结直肠癌(CRC)患病风险关系。方法检索CNKI、CBM、VIP、Pubmed、Embase等数据库,搜集有关XPD Lys751 Gln基因多态性与结直肠癌易感性的病例对照研究,提取纳入文献的相关数据进行Meta分析。以病例组及对照组XPD Lys751 Gln基因型分布的比值比(OR)为效应指标,对纳入的文献进行异质性检验,应用RevMan 5.14软件对原始数据合并分析,计算合并OR值及其95%可信区间(CI)。结果共13个病例对照研究符合纳入标准,累计病例3411例,对照5568例。Meta分析结果显示:Gln/Gln基因型与结直肠癌之间无关联性(P>0.05);亚组分析:混合人群组,各基因型之间比较,均无统计学差异(P>0.05)。亚洲人组:Gln/Gln vs.Lys/Lys,OR=2.27,95%CI=0.96~5.37,I2=72%,P=0.06;Lys/Gln+Gln/Gln vs.Lys/Lys,OR=1.17,95%CI=1.00~1.37,I2=0%,P=0.04;Gln-allele vs.Lys-allele,OR=1.17,95%CI=1.02~1.33,I2=0%,P=0.02。结论 XPD751 Gln/Gln基因分型可能增加亚洲人群罹患结直肠癌的风险,结果尚需更大样本、设计更严谨的研究加以证实。
Objective To investigate the relationship between XPD751 gene polymorphism and the risk of colorectal cancer (CRC). The method of retrieving CNKI, CBM, VIP, Pubmed, Embase database, etc., to collect information on susceptibility gene polymorphisms and colorectal cancer cases XPD Lys751 Gln-control study, extract relevant data into the Meta-analysis of the literature. In the case group and control group XPD Lys751 Gln genotype odds ratio (OR) for the effect index, on the literature included heterogeneity test application software RevMan 5.14 pooled analysis of the raw data, calculation and 95% pooled OR Confidence Interval (CI). Results A total of 13 case-control studies met the inclusion criteria, with a total of 3411 cases and 5568 controls. Meta analysis showed no correlation between Gln / Gln genotypes and colorectal cancer (P> 0.05). Subgroup analysis: There was no significant difference between mixed groups and genotypes (P> 0.05 ). Gln / Gln vs. Lys / Lys, OR = 2.27, 95% CI = 0.96 ~ 5.37, I2 = 72%, P = , 95% CI = 1.00-1.37, I2 = 0%, P = 0.04; Gln-allele vs. Lys-allele, OR = 1.17, 95% CI = 1.02-1.33, I2 = 0%, P = 0.02. Conclusions Genotyping of XPD751 Gln / Gln may increase the risk of colorectal cancer in Asian populations. The results require larger samples and more rigorous design studies to confirm.